<DOC>
	<DOC>NCT01159171</DOC>
	<brief_summary>This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patients &gt;=18 years of age Locally advanced or metastatic colorectal cancer No previous treatment with chemotherapy for metastatic disease Measurable and/or evaluable lesions Radiotherapy within 4 weeks before study Untreated brain metastases or primary brain tumors Chronic, daily treatment with highdose aspirin (&gt;325mg/day) Coexisting malignancies, or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>